Net clinical benefit of new oral anticoagulants (dabi-gatran, rivaroxaban, apixaban) versus no treat- ment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study - Banerjee, A; Lane, DA; Torp-Pedersen, C (Thromb Haemost, 2012)